PILGRIM: Phase III Clinical Trial in Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer Patients after Radical Gastrectomy with D2 Lymphadenectomy(hipec-01).

Shu-zhong Cui,Han Liang,Yong Li,Yanbing Zhou,Kaixiong Tao,Zhiwei Zhou,Guoxin Li,Peiyu Li,Baojun Zhou,Hongliang Yao,Zheng Peng,Bin Xiong,Minghui Pang,Shirong Cai,Jin Wan,Bin Liang,Ziying Lei,Jiping Wang
DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.4538
IF: 45.3
2020-01-01
Journal of Clinical Oncology
Abstract:4538 Background: Gastric cancer remains the 3rd leading cancer related death worldwide due to early disease recurrence. We hypothesize that hyperthermic intraperitoneal chemotherapy (HIPEC) may effectively prevent local regional recurrence for locally advanced gastric cancer patients who received curative intent surgery. Methods: Pathology proven gastric cancer patients with clinical T3/T4NxM0 disease are eligible for the study and will be randomized to either control group, who will receive standard radical gastrectomy and D2 lymph node dissection or HIPEC group, who will receive the same surgery and HIPEC with paclitaxel x 2 within the first week after surgery. All patients will receive either XELOX or SOX adjuvant chemotherapy. The primary end point is overall survival. Results: 648 patients from 16 high volume gastric medical centers were enrolled between May, 2015 and March, 2019. 331 and 317 patients were randomized to control and HIPEC groups respectively. The median follow-up time is 12.1 months. The common grade 3/4 toxicities ( > 5%) in control and HIPEC groups are anemia 6% vs. 4.1%, intraabdominal infection 5.4% vs. 3.8%, pneumonia 9.7% vs. 9.8%, fever 10.6% vs. 11.4% and hypoalbunemia 15.1% vs. 16.7% respectively. All three perioperative death (within 30 days after surgery) occurred in control group. One patient died from duodenum stump leak which led to multiple organ failure. One patient died from anastomotic led to intraabdominal infection and shock. The 3rd death was suicide caused by severe depression. At the time of this report, the number of event has not reached for final efficacy analysis. Conclusions: It is safe to administer HIPEC to patients received radical gastrectomy with D2 lymph node dissection within one week of surgery. The primary analysis will be expected in one year. Clinical trial information: NCT02356276 .
What problem does this paper attempt to address?